Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients

被引:115
作者
Wozniacka, A
Lesiak, A
Narbutt, J
McCauliffe, DP
Sysa-Jedrezejowska, A
机构
[1] Med Univ Lodz, Dept Dermatol, PL-94107 Lodz, Poland
[2] Rutland Reg Med Ctr, Dept Med, Rutland, VT USA
关键词
chloroquine; cytokine; interleukin; lupus erythematosus; tumor necrosis factor;
D O I
10.1191/0961203306lu2299oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis. Published data have revealed that serum levels of proinflammatory cytokines are increased in SLE patients. The aim of our study was to evaluate whether monotherapy with chloroquine phosphate affects IL-1 beta, IL-6, IL-18 and TNF-alpha serum levels in SLE patients. The study group consisted of 25 SLE patients with mild or moderate disease activity and 25 age- and sex-matched healthy control subjects. In SLE patients the cytokine levels were measured just before and three months after starting chloroquine treatment at a dose of 125 mg twice daily. Although the majority of SLE patients had a low systemic lupus activity measure (SLAM) index, the levels of IL-6, IL-18 and TNF-alpha were significantly higher than in the control group. After three-months of chloroquine therapy the mean level of IL-6, IL-18 and TNF-alpha decreased significantly. Minimal erythema doses (MEDs) were significantly increased in SLE patients after three months of chloroquine therapy. The results indicate that chloroquine treatment lowers some proinflammatory cytokines and may provide a photoprotective effect.
引用
收藏
页码:268 / 275
页数:8
相关论文
共 63 条
[1]   INTERLEUKIN-1 AND INTERLEUKIN-6 ACTIVITIES ARE INCREASED IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH CNS LUPUS-ERYTHEMATOSUS AND CORRELATE WITH LOCAL LATE T-CELL ACTIVATION MARKERS [J].
ALCOCERVARELA, J ;
ALEMANHOEY, D ;
ALARCONSEGOVIA, D .
LUPUS, 1992, 1 (02) :111-117
[2]   PRODUCTION OF INTRACELLULAR AND EXTRACELLULAR INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA BY PERIPHERAL-BLOOD MONOCYTES FROM PATIENTS WITH CONNECTIVE-TISSUE DISEASES [J].
AOTSUKA, S ;
NAKAMURA, K ;
NAKANO, T ;
KAWAKAMI, M ;
GOTO, M ;
OKAWATAKATSUJI, M ;
KINOSHITA, M ;
YOKOHARI, R .
ANNALS OF THE RHEUMATIC DISEASES, 1991, 50 (01) :27-31
[3]   SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus [J].
Aringer, M ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2003, 5 (04) :172-177
[4]   Increased bioactive TNF in human systemic lupus erythematosus:: associations with cell death [J].
Aringer, M ;
Feierl, E ;
Steiner, G ;
Stummvoll, GH ;
Höfler, E ;
Steiner, CW ;
Radda, I ;
Smolen, JS ;
Graninger, WB .
LUPUS, 2002, 11 (02) :102-108
[5]   Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1β and tumor necrosis factor α in macrophages:: Implications for their mode of action in rheumatoid arthritis [J].
Bondeson, J ;
Sundler, R .
GENERAL PHARMACOLOGY, 1998, 30 (03) :357-366
[6]   IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease [J].
Bossù, P ;
Neumann, D ;
Del Giudice, E ;
Ciaramella, A ;
Gloaguen, I ;
Fantuzzi, G ;
Dinarello, CA ;
Di Carlo, E ;
Musiani, P ;
Meroni, PL ;
Caselli, G ;
Ruggiero, P ;
Boraschi, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14181-14186
[7]   ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].
CARSWELL, EA ;
OLD, LJ ;
KASSEL, RL ;
GREEN, S ;
FIORE, N ;
WILLIAMSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670
[8]   Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus [J].
Chang, DM .
IMMUNOLOGICAL INVESTIGATIONS, 1997, 26 (5-7) :649-659
[9]   Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin [J].
Coban, C ;
Ishii, KJ ;
Kawai, T ;
Hemmi, H ;
Sato, S ;
Uematsu, S ;
Yamamoto, M ;
Takeuchi, O ;
Itagaki, S ;
Kumar, N ;
Horii, T ;
Akira, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (01) :19-25
[10]  
DANIS VA, 1991, DRUG EXP CLIN RES, V17, P549